Basal Cell and Cutaneous Squamous Cell Carcinomas: Diagnosis and Treatment

 

Am Fam Physician. 2020 Sep 15;102(6):339-346.

  Patient information: A handout on this topic is available at https://familydoctor.org/condition/skin-cancer/.

Related editorial: Keratinocyte Carcinomas: Should We Screen for Them?

Author disclosure: No relevant financial affiliations.

Keratinocyte carcinoma, traditionally referred to as nonmelanoma skin cancer, includes basal cell and cutaneous squamous cell carcinoma and is the most common skin cancer malignancy found in humans. The U.S. Preventive Services Task Force recommends counseling about minimizing exposure to ultraviolet radiation for people aged six months to 24 years with fair skin types to decrease their risk of skin cancer. Routine screening for skin cancer is controversial. The U.S. Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of a routine whole-body skin examination to screen for skin cancer. Basal cell carcinoma commonly appears as a shiny, pearly papule with a smooth surface, rolled borders, and arborizing telangiectatic surface vessels. Cutaneous squamous cell carcinoma commonly appears as a firm, smooth, or hyperkeratotic papule or plaque, and may have central ulceration. Initial tissue sampling for diagnosis is a shave technique if the lesion is raised, or a punch biopsy of the most abnormal-appearing area of skin. High-risk factors for recurrence and metastasis include prior tumors, ill-defined borders, aggressive histologic patterns, and perineural invasion. Mohs micrographic surgery has the lowest recurrence rate among treatments but is best considered for large, high-risk tumors or tumors in sensitive anatomic locations. Smaller, lower-risk tumors are treated with surgical excision, electrodesiccation and curettage, or cryotherapy. Topical imiquimod and fluorouracil are also treatment options for superficial basal cell carcinoma and squamous cell carcinoma in situ. There are no clear guidelines for follow up after an index keratinocyte carcinoma, but monitoring for recurrence is important because the five-year risk of subsequent skin cancer is 41%. After more than one diagnosis, the five-year risk increases to 82%.

Keratinocyte carcinoma, referred to as nonmelanoma skin cancer, comprises basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC). BCC is the most common skin cancer malignancy and affects more than 3.3 million people annually in the United States.1 CSCC is the second most common skin cancer, with up to 400,000 U.S. cases and more than 3,000 disease-related deaths annually.2 Lifetime risk of keratinocyte carcinoma in the United States is at least 20% and is greater than 30% for White patients.3

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingComments

Basal cell carcinoma and cutaneous squamous cell carcinoma should be primarily treated with surgical excision.1

C

Expert consensus

High-risk tumors and tumors with more invasive histologic subtypes (micronodular, infiltrative, and morpheaform) are best treated with Mohs micrographic surgery.22

B

Randomized trial comparing outcomes with standard excision to Mohs micrographic surgery

Excision of basal cell carcinoma with pathology demonstrating tumor at the surgical margin, should be followed by immediate reexcision or Mohs micrographic surgery.24

B

Diagnostic cohort study evaluating tumor recurrence after incomplete excision

Cryotherapy should be considered for low-risk lesions only when more effective therapies are contraindicated or impractical.1,2

C

Clinical guideline from specialty society

Superficial basal cell carcinoma in low-risk sites may be treated with topical 5% imiquimod (Aldara) or 5% fluorouracil.1

C

Clinical guideline from the American Academy of Dermatology


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

The Author

JONATHON M. FIRNHABER, MD, MAEd, MBA, FAAFP, is vice chair of Academic Affairs, associate professor, and residency program director in the Department of Family Medicine at the Brody School of Medicine at East Carolina University, Greenville, N.C.

Address correspondence to Jonathon M. Firnhaber, MD, MAEd, MBA, East Carolina University, Family Medicine Center, 101 Heart Dr., Greenville, NC 27834 (email: firnhaberj@ecu.edu). Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

References

show all references

1. Kim JYS, Kozlow JH, Mittal B, et al.; Work Group; Invited Reviewers. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540–559....

2. Kim JYS, Kozlow JH, Mittal B, et al.; Work Group; Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560–578.

3. Cameron M, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2018;80(2):303–317.

4. Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010;(4):CD007869.

5. Wei EX, Li X, Nan H. Extremity nevus count is an independent risk factor for basal cell carcinoma and melanoma, but not squamous cell carcinoma. J Am Acad Dermatol. 2019;80(4):970–978.

6. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–983.

7. Grossman DC, Curry SJ, Owens DK, et al.; US Preventive Services Task Force. Behavioral counseling to prevent skin cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(11):1134–1142.

8. Wernli KJ, Henrikson NB, Morrison CC, et al. Screening for skin cancer in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(4):436–447.

9. Sánchez G, Nova J, Rodriguez-Hernandez A, et al. Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database of Syst Rev. 2016;(7):CK011161.

10. Green A, Williams G, Nèale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial [published correction appears in Lancet. 1999;354(9183):1038]. Lancet. 1999;354(9180):723–729.

11. Zhang M, Qureshi AA, Geller AC, et al. Use of tanning beds and incidence of skin cancer. J Clin Oncol. 2012;30(14):1588–1593.

12. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: contemporary approaches to diagnosis, treatment, and prevention [published correction appears J Am Acad Dermatol. 2019;81(1):310]. J Am Acad Dermatol. 2019;80(2):321–339.

13. Tanese K. Diagnosis and management of basal cell carcinoma. Curr Treat Options Oncol. 2019;20(2):13.

14. Rosen T, Lebwohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68(suppl 1):S2–S9.

15. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–966.

16. Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med. 2018;379(4):363–374.

17. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs topical tretinoin chemoprevention trial. Cancer. 2009;115(11):2523–2530.

18. Dirschka T, Gupta G, Micali G, et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office–based dermatology. J Dermatolog Treat. 2017;28(5):431–442.

19. Maloney ME, Jones DB, Sexton FM. Pigmented basal cell carcinoma: investigation of 70 cases. J Am Acad Dermatol. 1992;27(1):74–78.

20. Welsch MJ, Troiani BM, Hale L, et al. Basal cell carcinoma characteristics as predictors of depth of invasion. J Am Acad Dermatol. 2012;67(1):47–53.

21. Bath-Hextall FJ, Matin RN, Wilkinson D, et al. Interventions for cutaneous Bowen's disease. Cochrane Database Syst Rev. 2013;(6):CD007281.

22. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007;(1):CD003412.

23. van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011–3020.

24. Robinson JK, Fisher SG. Recurrent basal cell carcinoma after incomplete resection. Arch Dermatol. 2000;136(11):1318–1324.

25. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol. 2007;56(1):91–95.

26. Kuflik EG. Cryosurgery for cutaneous malignancy. An update. Dermatol Surg. 1997;23(11):1081–1087.

27. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–1438.

28. Martinez JC, Otley CC. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc. 2001;76(12):1253–1265.

29. Wehner MR, Linos E, Parvataneni R, et al. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol. 2015;151(4):382–388.

30. Wu S, Cho E, Li WQ, et al. History of keratinocyte carcinoma and risk of melanoma: a prospective cohort study. J Natl Cancer Inst. 2017;109(4).

31. Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician. 2012;86(2):161–168. Accessed April 3, 2020. https://www.aafp.org/afp/2012/0715/p161.html

32. Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinomas. Am Fam Physician. 2004;70(8):1481–1488. Accessed April 3, 2020. https://www.aafp.org/afp/2004/1015/p1481.html

33. Jerant AF, Johnson JT, Sheridan CD, et al. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62(2):357–368. Accessed April 3, 2020. https://www.aafp.org/afp/2000/0715/p357.html

 

 

Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article